ACG 2022 Annual Scientific Meeting
21-26 October 2022
ACG 2022 Annual Scientific Meeting, Charlotte Convention Center
Charlotte, North Carolina
Resonance Health will be attending …
21-26 October 2022
ACG 2022 Annual Scientific Meeting, Charlotte Convention Center
Charlotte, North Carolina
Resonance Health will be attending …
{loadposition asx-announcements-2022}
Resonance Health Ltd has today signed a Patient Access to FerriSmart® Letter of Agreement with the World Health Organization related Cyprus based Thalassaemia International Federation (TIF).
Resonance Health Ltd has today signed a Patient Access to FerriSmart® Letter of Agreement with the World Health Organization related Cyprus based Thalassaemia International Federation (TIF).
Resonance Health Ltd announces the development of its newest AI medical device, LiverSmart, which is now undergoing final quality and verification checks prior to its submission to the United States Food & Drug Administration (FDA) for regulatory clearance.
LiverSmart combines two existing regulatory-cleared Resonance Health products, FerriSmart® and HepaFat-AI®, into a single multi-parametric MRI session, avoiding the need for multiple MRI appointments, and delivering a more complete and comprehensive assessment of a person’s liver.
Resonance Health Ltd announces the development of its newest AI medical device, LiverSmart, which is now undergoing final quality and verification checks prior to its submission to the United States Food & Drug Administration (FDA) for regulatory clearance. LiverSmart combines two existing regulatory-cleared Resonance Health products, FerriSmart® and HepaFat-AI®, into a single multi-parametric MRI session, …
8 October 2021 ACG 2021 Annual Scientific Meeting, American College of Gastroenterology Mandalay Bay, Las Vegas Resonance Health will be attending the ACG 2021 Annual Scientific Meeting and Postgraduate Course hosted by the American College of Gastroenterology on 22-27 October 2021.
Resonance Health attended the EASL Digital NAFLD Summit 2021 on 16 – 17 September and participated with insights into developments in artificial intelligence-based approaches to NAFLD management using HepaFat-AI.
Resonance Health attended the EASL Digital NAFLD Summit 2021 on 16 – 17 September and participated with insights into developments in artificial intelligence-based approaches to NAFLD management using HepaFat-AI.
Resonance Health Ltd (ASX: RHT) (“Resonance Health” or “Company”) advises that Mr. Ajay Nair has been appointed to the new role of General Manager – Global Sales & Marketing.